---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-039219"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:39:38.012956+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Personalis reports FY24 revenue $84.6M (+15% YoY); provides FY25 guidance with $80-90M revenue, net loss ~$85M

## Summary
- FY24 revenue $84.6M (+15% YoY); net loss $81.3M vs $108.3M in FY23; cash $185M including $50M Merck investment.
- Q4 revenue $16.8M (-15% YoY); delivered 1,441 molecular tests in Q4 (+52% QoQ); FY24 tests 3,285 vs 177 in FY23.
- Guidance: FY25 revenue $80-90M, gross margin 21-23%, net loss ~$85M, cash usage $75-80M (up from $47M in FY24).
- Business highlights: submitted for Medicare coverage in early-stage breast cancer; multi-year Moderna extension; expanded Tempus deal.

## SEC filing metadata
- accession: 0001193125-25-039219
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312525039219/0001193125-25-039219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312525039219/d933582d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-039219
- JSON: https://secwatch.observer/filing/0001193125-25-039219.json
- Plain text: https://secwatch.observer/filing/0001193125-25-039219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.